MedDataX Logo

Tezepelumab PRO Study

NCT ID: NCT05922891

Last Updated: 2025-09-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

92 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-09-27

Study Completion Date

2025-09-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study assesses the impact of tezepelumab treatment not only on asthma control but also on cough specific Health-Related Quality of Life (HRQoL). Asthma control can be evaluated using Asthma Control Questionnaire (ACQ). Cough symptom which is one of the symptoms related airway hyperresponsiveness can be assessed via the relevant questionnaire, Leicester Cough Questionnaire (LCQ). There is moderate negative correlation between ACQ and LCQ . Improvements in both asthma control and cough symptom by tezepelumab would clarify effectiveness of Tezepelumab in real-world. Though Tezepelumab is recently approved in Japan, there is no real-world evidence on tezepelumab, particularly on above mentioned symptoms.

Thus, this study aims to estimate effectiveness of tezepelumab on asthma and cough symptoms in real world settings.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Tezepelumab Treatment in Korean Severe Asthma Patients

NCT06438913

Asthma
NOT_YET_RECRUITING

Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States

NCT05329194

Asthma
COMPLETED PHASE4

TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

NCT05729711

Bronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)
ACTIVE_NOT_RECRUITING

Study to Evaluate Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma

NCT05274815

Asthma
COMPLETED PHASE3

A Study for Observing Severe Asthma in Patients Treated With Tezepelumab

NCT05677139

Asthma
ACTIVE_NOT_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients aged ≥18 years who provide informed consent and who receive new prescription of Tezepelumab as per the physician's decision at baseline according to the package insert saying "Tezepelumab is given to patient with asthma (limited to severe or refractory patient whose asthma symptoms cannot be controlled even with existing treatment)"
2. ACQ-6 ≥1.5 at baseline
3. Patients with persistent cough ≥8 weeks up until the baseline visit according to The Japanese Respiratory Society Guidelines for the Management of Cough and Sputum 2019

Exclusion Criteria

1. Patients who had asthma exacerbation within one month before study enrollment
2. Patients who had the biologics treatment in following period prior to the enrollment

* omalizumab in 2 or 4 weeks depending on the body weight and total IgE amount
* mepolizumab in 4 weeks
* Benralizumab in 8 weeks
* Dupilumab in 2 weeks
3. Patients with cough related diseases other than asthma as determined by treating physicians
4. Patients participating in studies that affect this study (study with other interventional treatment to evaluate efficacy/safety of treatment in patients with cough, asthma, or allergic/eosinophilic diseases)
5. Any disorder, including heart failure, malignancy, morbid obesity(BMI≧35) , respiratory infectious disease that is not stable (e.g. patients who need medical treatment) in the opinion of the investigator and could:

* Affect the safety of the patient throughout the study
* Impede the patient's ability to complete the entire duration of study
6. Patients with pregnancy or lactation period
Minimum Eligible Age

18 Years

Maximum Eligible Age

130 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Aomori, , Japan

Site Status

Research Site

Bunkyō City, , Japan

Site Status

Research Site

Fujisawa, , Japan

Site Status

Research Site

Fukuoka, , Japan

Site Status

Research Site

Fukushima, , Japan

Site Status

Research Site

Hamamatsu, , Japan

Site Status

Research Site

Hiroshima, , Japan

Site Status

Research Site

Iizuka, , Japan

Site Status

Research Site

Izumo, , Japan

Site Status

Research Site

Kawasaki, , Japan

Site Status

Research Site

Kitakyushu, , Japan

Site Status

Research Site

Kiyose, , Japan

Site Status

Research Site

Kurashiki, , Japan

Site Status

Research Site

Matsusaka, , Japan

Site Status

Research Site

Minami, , Japan

Site Status

Research Site

Minato, , Japan

Site Status

Research Site

Nagoya, , Japan

Site Status

Research Site

Naka, , Japan

Site Status

Research Site

Niigata, , Japan

Site Status

Research Site

Nishinomiya, , Japan

Site Status

Research Site

Osaka, , Japan

Site Status

Research Site

Sapporo, , Japan

Site Status

Research Site

Shinagawa City, , Japan

Site Status

Research Site

Shinjuku, , Japan

Site Status

Research Site

Shizuoka, , Japan

Site Status

Research Site

tabashi City, , Japan

Site Status

Research Site

Tennōjichō-kita, , Japan

Site Status

Research Site

Ube, , Japan

Site Status

Research Site

Yonago, , Japan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Japan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D5180R00025

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain
NCT07013760 COMPLETED
Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma
NCT03927157 COMPLETED PHASE3
Tezepelumab on Airway Structure and Function in Patients With Uncontrolled Moderate-to-severe Asthma
NCT05280418 COMPLETED PHASE3
Long-term Safety of Tezepelumab in Japanese Subjects With Inadequately Controlled Severe Asthma
NCT04048343 COMPLETED PHASE3
REVErsing Airway Remodelling With Tezepelumab
NCT05651841 RECRUITING PHASE3
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589 RECRUITING PHASE3
Study to Evaluate Tezepelumab in Adults & Adolescents With Severe Uncontrolled Asthma
NCT03347279 COMPLETED PHASE3
Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
NCT03406078 COMPLETED PHASE3
Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
NCT03706079 COMPLETED PHASE3
Patient Characteristics, Treatment Patterns and Outcomes of Patients With Severe Asthma Treated With Tezepelumab in the Real World; a Retrospective, Observational Medical Chart Review Conducted in UK Severe Asthma Centres
NCT06455462 COMPLETED
Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma
NCT05062759 COMPLETED PHASE3
Tezepelumab Home Use Study
NCT03968978 COMPLETED PHASE3
Asthma Control, Quality of Life and Emotional Feelings in a Real Life Setting
NCT02640742 COMPLETED
Observational Study on the Clinical Profile of Patients With Uncontrolled Severe Asthma Treated With Tezepelumab in Italy
NCT06948396 RECRUITING
Observational Retrospective Study To Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab in the Framework Of Use in Special Situations Prior to Commercialisation in Spain
NCT06487065 COMPLETED
Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma
NCT05740748 UNKNOWN PHASE2
Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
NCT06998095 NOT_YET_RECRUITING
Long-Term Study of IGE025 in Moderate to Severe Bronchial Asthma.
NCT00219323 COMPLETED PHASE3
A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma
NCT02902809 TERMINATED PHASE3
Tezspire Cardiac Events PASS
NCT06951867 RECRUITING
The Effect of Long Term Inhaled Corticosteroids on the Risk of Cardiovascular Morbidities
NCT00959257 COMPLETED
Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in Russia
NCT06566885 ACTIVE_NOT_RECRUITING
Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma
NCT04673630 COMPLETED PHASE1
Impact of Comorbidities, Some Biomarkers, Micro RNA in Childhood Asthma Phenotypes
NCT07230912 NOT_YET_RECRUITING
Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
NCT02555683 COMPLETED PHASE3